1. Home
  2. AIRT vs CELU Comparison

AIRT vs CELU Comparison

Compare AIRT & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Air T Inc.

AIRT

Air T Inc.

HOLD

Current Price

$18.75

Market Cap

61.2M

ML Signal

HOLD

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$1.11

Market Cap

50.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIRT
CELU
Founded
1980
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Air Freight/Delivery Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.2M
50.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AIRT
CELU
Price
$18.75
$1.11
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
2.1K
79.4K
Earning Date
02-11-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$279,216,000.00
$40,578,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$76.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.56
$1.00
52 Week High
$26.70
$4.35

Technical Indicators

Market Signals
Indicator
AIRT
CELU
Relative Strength Index (RSI) 39.68 28.84
Support Level $19.00 $1.25
Resistance Level $20.75 $1.37
Average True Range (ATR) 0.45 0.15
MACD 0.00 -0.03
Stochastic Oscillator 12.90 2.73

Price Performance

Historical Comparison
AIRT
CELU

About AIRT Air T Inc.

Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: